01NEXGEL will report Q3 2026 earnings on November 10 after market close with expected EPS of -$4.80, significantly worse than the -$0.00 reported in Q3 2025.
02Revenue is expected to reach $4.2M, showing year-over-year growth despite the company's ongoing losses.
03The stock trades at $3.60 with a $19.4M market capitalization as a healthcare company.
04Recent quarterly results show worsening EPS surprises: Q2 missed by -233%, Q1 by -57%, and Q4 2025 by -33%.
05Investors should assess revenue trends, margins, and guidance rather than focusing solely on the negative EPS figure.
Earnings Results
NEXGEL, Inc. (NASDAQ:NXGL) is scheduled to report its Q3 earnings results on November 10, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-4.80, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at $4.2M, up from a year ago.
Company Overview
The stock currently trades at $3.60 with a market capitalization of $19.4M.
Ahead of NEXGEL, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking NEXGEL, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.